Duchenne muscular dystrophy: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• DMD 9
• ATM 0
• SIRT1 0
• EGFR 0
• AMPK 0
• HDAC 0
• mTOR 0
• SGLT2 1
• TNF 0
• CFTR 1
• CTLA-4 0
• G6PD 0
• GLP-1 0
• HTT 1
• IL-23 0
• IL-6 0
• NF1 1
• NRF2 0
• PINK1 0
• PPAR 0
• SMN1 1
• STK11 0
• TTR 1
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Syriac Education, Abbasid Times: Reclaiming the Place of Syriac Intellectual Training under Muslim Rulers (SEAT)

  Universita Degli Studi di Catania· Catania, Italy· EU contribution €209,483· until Feb 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeted Genetic Manipulation of Muscle Stem Cells in vivo Towards New Treatment Strategies Against Muscular Dystrophies (StemAAV)

  Institut Pasteur· Paris, France· EU contribution €150,000· until May 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  SKeletal Muscle - REgulation of FORce and Maturation through Tubulin isotypes (SKM-REFORMAT)

  Universite Lyon 1 Claude Bernard· Villeurbanne Cedex, France· EU contribution €242,261· until Jan 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Exploiting Transcriptional Adaptation to Develop New Genetic Compensation-based Therapies (TA2TRSQ)

  Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev· Munchen, Germany· EU contribution €150,000· until Feb 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Deciphering the role of protein S-palmitoylation in skeletal muscle physiopathology (MyoPALM)

  Universita Degli Studi di Padova· Padova, Italy· EU contribution €320,924· until Aug 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Between Canon and Coincidence: using data-driven approaches to understand Art Worlds (BECACO)

  Universiteit Leiden· Leiden, Netherlands· EU contribution €1,498,695· until Dec 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Next-generation models and genetic therapies for rare neuromuscular diseases (MAGIC)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €6,553,472· until May 2027· 11 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Circular RNA Therapeutics for Duchenne Muscular Dystrophy (circRNA4DMD)

  Tel Aviv University· Tel Aviv, Israel· EU contribution €2,500,000· until Dec 2027

• European Commission (Horizon 2020) · ERC-ADG

  Cardiac open reading frame edition to study cardiomyopathies in pigs (Cor-Edit-P)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €2,499,375· until Dec 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon 2020) · ERC-ADG

  Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy. (UniMab)

  Ospedale San Raffaele Srl· Milano, Italy· EU contribution €2,345,625· until Dec 2026

  The disease is named only in the funder's project summary, not in the title.

10 of 10 running projects, newest first. Listed amounts together: €16.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 2
• Organoids 3
• CRISPR-Cas Systems 13
• Gene Expression Profiling 7
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 4
• Exome Sequencing 5
• Proteomics 13
• Metabolomics 1
• Mass Spectrometry 2
• Immunohistochemistry 3
• Magnetic Resonance Imaging 19
• Machine Learning 2
• Cohort Studies 8

• Integrated RNA sequencing and in vivo biosensor imaging define the early pathogenic cascade of Duchenne muscular dystrophy.

  Transl Res, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.